Search for a doctor

Aliya Gulamhusein, M.D.

  1. Hepatologist
Request an Appointment

Publications

  1. Nguyen B, Quon S, Powar A, Montano-Loza A, Gulamhusein A, Chahal D. Comparative waitlist mortality of autoimmune liver disease: A systematic review and meta-analysis. Transplant Rev (Orlando). 2026 Jul; 40 (3):101024 Epub 2026 Apr 22
    View PubMed
  2. Bowlus CL, Bittencourt PL, Bobat B, Gulamhusein A, Kowdley K, Levy C, Lleo A, Ma X, Tanaka A. Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective. Am J Gastroenterol. 2026 May 18 [Epub ahead of print]
    View PubMed
  3. Leung KK, Li W, Hansen B, Gulamhusein A, Lapointe-Shaw L, Ricciuto A, Benchimol EI, Flemming JA, Hirschfield GM. Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort. Hepatology. 2026 Feb 4 Epub 2026 Feb 04
    View PubMed
  4. Wong YJ, Lam L, Soret PA, Lemoinne S, Hansen B, Hirschfield G, Gulamhusein A, Lytvyak E, Pares A, Olivas I, Londono MC, Rogriguez-Tajes S, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Levy C, Tanaka A, Dumortier J, Pageaux GP, de Lédinghen V, Carrat F, Chazouillères O, Corpechot C, Montano-Loza AJ, Global & ERN Rare-Liver PBC Study Groups. Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis. J Hepatol. 2026 Feb; 84(2):275-283. Epub 2025 Oct 03.
    View PubMed
  5. Singh Y, Eaton JE, Venkatesh SK, Welle CL, Smith B, Faghani S, Vesterhus M, Karlsen TH, Jorgensen KK, Folseraas T, Petrovic K, Negard A, Bjoerk I, Abildgaard A, Gulamhusein AF, Jhaveri K, Gores GJ, Ilyas SI, Taner T, Heimbach JK, Diwan TS, LaRusso NF, Lazaridis KN, Erickson BJ. Deep learning analysis of MRI accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis. Hepatology. 2026 Jan 01; 83(1):30-39. Epub 2025 Mar 20.
    View PubMed
  6. Taylor SA, Bader GD, MacParland S, Mullen AC, Andrews T, Cuenca AG, DasGupta R, Gehring AJ, Grun D, Guilliams M, Gulamhusein A, Henderson NC, Hirschfield G, Huppert SS, Itzkovitz S, Jiang ZG, Lauer GM, McGilvray I, Mysore KR, Pirola CJ, Quon G, Rahbari M, Regev A, Ricciuto A, Scott CL, Sharma A, Sookoian S, Tana MM, Teichmann SA, Vallier L, Vlachos IS, Wang B, Zhen M. Towards a reference cell atlas of liver diversity over the human lifespan. Nat Rev Gastroenterol Hepatol. 2026 Jan; 23 (1):97-109 Epub 2025 Oct 13
    View PubMed
  7. Leung KK, Youssef M, Xiao Y, Streutker C, Gulamhusein A, Hansen B, Calo N, May G, Mosko J, Hirschfield GM. Endoscopic retrograde cholangiopancreatography and primary sclerosing cholangitis: a retrospective study of a high-volume program. J Can Assoc Gastroenterol. 2025 Dec; 8 (6):228-234 Epub 2025 Aug 06
    View PubMed
  8. Natt N, Jones May T, Malhi G, Dumond J, Gulamhusein A, Tandon P. Infections in primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. J Can Assoc Gastroenterol. 2025 Oct; 8 (5):163-178 Epub 2025 Sept 03
    View PubMed
  9. Cancado GGL, Chen B, Cameron M, Houri I, Leung KK, Gulamhusein AF, Hansen B, Hirschfield GM. High biochemical remission rates in patients with primary biliary cholangitis treated with "triple" anticholestatic therapy. Hepatol Commun. 2025 Oct 1; 9 (10) Epub 2025 Sept 29
    View PubMed
  10. Cancado GGL, Deeb M, Gulamhusein AF. Liver transplantation for cholestatic liver diseases: Timing and disease recurrence. Hepatology. 2025 Oct 1; 82 (4):1016-1035 Epub 2025 Feb 17
    View PubMed
  11. Levy C, Trivedi PJ, Kowdley KV, Gordon SC, Bowlus CL, Londono MC, Hirschfield GM, Gulamhusein A, Lawitz EJ, Vierling JM, Mayo MJ, Jacobson IM, Kremer AE, Corpechot C, Jones D, Buggisch P, Zhuo S, Proehl S, Heusner C, McWherter CA, Crittenden DB, ASSURE Investigators. Long-Term Efficacy and Safety of Selective PPARdelta Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. Am J Gastroenterol. 2025 Jun 24; 121 (5):1140-53 Epub 2025 June 24
    View PubMed
  12. Leung KK, Li W, Hansen B, Gulamhusein A, Lapointe-Shaw L, Shaheen AA, Ricciuto A, Benchimol EI, Flemming JA, Hirschfield GM. Primary sclerosing cholangitis-inflammatory bowel disease: Epidemiology, mortality, and impact of diagnostic sequence. JHEP Rep. 2025 Mar; 7 (3):101272 Epub 2024 Nov 30
    View PubMed
  13. Lam L, Soret PA, Lemoinne S, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Parés A, Olivas I, Londono MC, Rodríguez-Tajes S, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Levy C, Tanaka A, Dumortier J, Pageaux GP, de Lédinghen V, Carrat F, Chazouillères O, Corpechot C, Global & ERN Rare-Liver PBC Study Groups. Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2024 Dec; 22(12):2432-2441.e2. Epub 2024 Jul 15.
    View PubMed
  14. Roberts SB, Choi WJ, Worobetz L, Vincent C, Flemming JA, Cheung A, Qumosani K, Swain M, Grbic D, Ko HH, Peltekian KM, Abrahamyan L, Saini M, Tirona K, Aziz B, Lytvyak E, Invernizzi P, Ponsioen CY, Bruns T, Cazzagon N, Lindor K, Dalekos GN, Gatselis NK, Verhelst X, Floreani A, Corpechot C, Mayo MJ, Levy C, Londoño MC, Battezzati PM, Pares A, Nevens F, van der Meer A, Kowdley KV, Trivedi PJ, Lleo A, Thorburn D, Carbone M, Selzner N, Gulamhusein AF, Janssen H, Montano-Loza AJ, Mason AL, Hirschfield GM, Hansen BE, Canadian Network for Autoimmune Liver disease (CaNAL). Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis. JHEP Rep. 2024 Oct; 6(10):101168. Epub 2024 Jul 08.
    View PubMed
  15. Plagiannakos CG, Hirschfield GM, Lytvyak E, Roberts SB, Ismail M, Gulamhusein AF, Selzner N, Qumosani KM, Worobetz L, Hercun J, Vincent C, Flemming JA, Swain MG, Cheung A, Chen T, Grbic D, Peltekain K, Mason AL, Montano-Loza AJ, Hansen BE, Canadian Network for Autoimmune Liver Disease (CaNAL). Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study. J Hepatol. 2024 Aug; 81 (2):227-237 Epub 2024 Mar 24
    View PubMed
  16. Leibovitzh H, Nayeri S, Borowski K, Hernandez-Rocha C, Lee SH, Turpin W, Stempak JM, Sandhu I, Milgrom R, Smith MI, Croitoru K, Hirschfield GM, Gulamhusein A, Silverberg MS. Inflammatory bowel disease associated with primary sclerosing cholangitis is associated with an altered gut microbiome and bile acid profile. J Crohns Colitis. 2024 Jul 9; 18 (12):1957-66 Epub 2024 July 09
    View PubMed
  17. Andrews TS, Nakib D, Perciani CT, Ma XZ, Liu L, Winter E, Camat D, Chung SW, Lumanto P, Manuel J, Mangroo S, Hansen B, Arpinder B, Thoeni C, Sayed B, Feld J, Gehring A, Gulamhusein A, Hirschfield GM, Ricciuto A, Bader GD, McGilvray ID, MacParland S. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver. J Hepatol. 2024 May; 80 (5):730-743 Epub 2024 Jan 08
    View PubMed
  18. Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Pares A, Olivas I, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Dumortier J, Pageaux GP, de Lédinghen V, Chazouillères O, Carrat F, Global & ERN Rare-Liver PBC Study Groups. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology. 2024 Jan 01; 79(1):39-48. Epub 2023 Jul 03.
    View PubMed
  19. Onofrio F, Zheng K, Xu C, Chen S, Xu W, Vyas M, Bingham K, Patel K, Lilly L, Cattral M, Selzner N, Jaeckel E, Tsien C, Gulamhusein A, Hirschfield GM, Bhat M. Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis. Hepatol Commun. 2023 Aug 1; 7 (8) Epub 2023 Aug 03
    View PubMed
  20. Murillo Perez CF, Ioannou S, Hassanally I, Trivedi PJ, Corpechot C, van der Meer AJ, Lammers WJ, Battezzati PM, Lindor KD, Nevens F, Kowdley KV, Bruns T, Cazzagon N, Floreani A, Mason AL, Gulamhusein A, Ponsioen CY, Carbone M, Lleo A, Mayo MJ, Dalekos GN, Gatselis NK, Thorburn D, Verhelst X, Parés A, Londoño MC, Janssen HLA, Invernizzi P, Vuppalanchi R, Hirschfield GM, Hansen BE, Levy C, Global PBC Study Group. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival. Liver Int. 2023 Jul; 43(7):1497-1506. Epub 2023 May 08.
    View PubMed
  21. Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, Landis C, Muir AJ, Billin A, Xu J, Liu X, Lu X, Chung C, Myers RP, Kowdley KV. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC. Clin Gastroenterol Hepatol. 2023 Jun; 21 (6):1552-1560.e2 Epub 2022 Aug 04
    View PubMed
  22. Murillo Perez CF, Gerussi A, Trivedi PJ, Corpechot C, van der Meer AJ, Maria Battezzati P, Lindor KD, Nevens F, Kowdley KV, Bruns T, Cazzagon N, Floreani A, Tanaka A, Ma X, Mason AL, Gulamhusein A, Ponsioen CY, Carbone M, Lleo A, Mayo MJ, Dalekos GN, Gatselis NK, Thorburn D, Verhelst X, Parés A, Janssen HLA, Hirschfield GM, Hansen BE, Invernizzi P, Lammers WJ, GLOBAL PBC Study Group. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe. Eur J Gastroenterol Hepatol. 2023 Jan 01; 35(1):112-119. Epub 2022 Nov 17.
    View PubMed
  23. Xu J, Wang Y, Khoshdeli M, Peach M, Chuang JC, Lin J, Tsai WW, Mahadevan S, Minto W, Diehl L, Gupta R, Trauner M, Patel K, Noureddin M, Kowdley KV, Gulamhusein A, Bowlus CL, Huss RS, Myers RP, Chung C, Billin AN. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology. 2023 Jan 1; 77 (1):20-32 Epub 2022 July 17
    View PubMed
  24. Corpechot C, Carrat F, Gaouar F, Chau F, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Schramm C, Pares A, Olivas I, Eaton JE, Osman KT, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Dumortier J, Bruns T, Große K, Pageaux GP, Wetten A, Dyson J, Jones D, Chazouillères O, Hansen B, de Lédinghen V, Global & ERN Rare-Liver PBC Study Groups. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol. 2022 Dec; 77(6):1545-1553. Epub 2022 Jun 28.
    View PubMed
  25. Visseren T, Erler NS, Heimbach JK, Eaton JE, Selzner N, Gulamhusein A, van der Heide F, Porte RJ, van Hoek B, Alwayn IPJ, Metselaar HJ, IJzermans JNM, Darwish Murad S. Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study. JHEP Rep. 2022 Dec; 4(12):100599. Epub 2022 Oct 01.
    View PubMed
  26. Murillo Perez CF, Fisher H, Hiu S, Kareithi D, Adekunle F, Mayne T, Malecha E, Ness E, van der Meer AJ, Lammers WJ, Trivedi PJ, Battezzati PM, Nevens F, Kowdley KV, Bruns T, Cazzagon N, Floreani A, Mason AL, Parés A, Londoño MC, Invernizzi P, Carbone M, Lleo A, Mayo MJ, Dalekos GN, Gatselis NK, Thorburn D, Verhelst X, Gulamhusein A, Janssen HLA, Smith R, Flack S, Mulcahy V, Trauner M, Bowlus CL, Lindor KD, Corpechot C, Jones D, Mells G, Hirschfield GM, Wason J, Hansen BE, GLOBAL PBC Study Group and the members of the UK-PBC Consortium. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. Gastroenterology. 2022 Dec; 163(6):1630-1642.e3. Epub 2022 Sep 20.
    View PubMed
  27. Singh Y, Jons WA, Eaton JE, Vesterhus M, Karlsen T, Bjoerk I, Abildgaard A, Jorgensen KK, Folseraas T, Little D, Gulamhusein AF, Petrovic K, Negard A, Conte GM, Sobek JD, Jagtap J, Venkatesh SK, Gores GJ, LaRusso NF, Lazaridis KN, Erickson BJ. Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis. Eur Radiol Exp. 2022 Nov 18; 6(1):58.
    View PubMed
  28. Roberts SB, Hirschfield GM, Worobetz LJ, Vincent C, Flemming JA, Cheung A, Qumosani K, Swain M, Grbic D, Ko HH, Peltekian K, Selzner N, Abrahamyan L, Aziz B, Lytvyak E, Tirona K, Gulamhusein AF, Janssen HLA, Montano-Loza AJ, Mason AL, Hansen BE, Canadian Network for Autoimmune Liver Disease (CaNAL). Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis. Hepatology. 2022 Aug; 76 (2):303-316 Epub 2022 Mar 15
    View PubMed
  29. Broda CR, Alonso-Gonzalez R, Ghanekar A, Gulamhusein A, McDonald M, Luk A, Kobulnik J, Billia F, Heggie J, Jariani M, Honjo O, Barron D, Hickey E, Roche SL. Fate of the liver in the survivors of adult heart transplant for a failing Fontan circulation. J Heart Lung Transplant. 2022 Mar; 41 (3):283-286 Epub 2021 Nov 11
    View PubMed
  30. Lam CZ, Gulamhusein A, Wald RM. Liver Cirrhosis and Hepatocellular Carcinoma After the Fontan Operation: Reaching Clarity in the Face of Uncertainty. Circulation. 2021 Dec 21; 144 (25):1977-1980 Epub 2021 Dec 20
    View PubMed
  31. Murillo Perez CF, Gulamhusein A, Carbone M, Trivedi PJ, van der Meer AJ, Corpechot C, Battezzati PM, Lammers WJ, Cazzagon N, Floreani A, Parés A, Nevens F, Lleo A, Mayo MJ, Kowdley KV, Ponsioen CY, Dalekos GN, Gatselis NK, Thorburn D, Mason AL, Janssen H, Verhelst X, Bruns T, Lindor KD, Chazouillères O, Invernizzi P, Hansen BE, Hirschfield GM, GLOBAL PBC Study Group. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. Eur J Gastroenterol Hepatol. 2021 Dec 01; 33(1S Suppl 1):e266-e273.
    View PubMed
  32. Montano-Loza AJ, Allegretti JR, Cheung A, Ebadi M, Jones D, Kerkar N, Levy C, Rizvi S, Vierling JM, Alvarez F, Bai W, Gilmour S, Gulamhusein A, Guttman O, Hansen BE, MacParland S, Mason A, Onofrio F, Santamaria P, Stueck A, Swain M, Vincent C, Ricciuto A, Hirschfield G. Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. Can Liver J. 2021 Fall; 4(4):401-425. Epub 2021 Nov 11.
    View PubMed
  33. Leung KK, Deeb M, Fischer SE, Gulamhusein A. Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions. Semin Liver Dis. 2021 Aug; 41 (3):409-420 Epub 2021 June 28
    View PubMed
  34. Goet JC, Murillo Perez CF, Harms MH, Floreani A, Cazzagon N, Bruns T, Prechter F, Dalekos GN, Verhelst X, Gatselis NK, Lindor KD, Lammers WJ, Gulamhusein A, Reig A, Carbone M, Nevens F, Hirschfield GM, van der Meer AJ, van Buuren HR, Hansen BE, Pares A, GLOBAL PBC Study Group. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. Am J Gastroenterol. 2021 Jul 1; 116 (7):1514-1522
    View PubMed
  35. Roberts SB, Ismail M, Kanagalingam G, Mason AL, Swain MG, Vincent C, Yoshida EM, Tsien C, Flemming JA, Janssen HLA, Hirschfield GM, Hansen BE, Gulamhusein AF, Canadian Network for Autoimmune Liver Disease. Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. Hepatol Commun. 2020 Sep; 4 (9):1332-1345 Epub 2020 July 06
    View PubMed
  36. Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Pares A, Janssen HLA, Hansen BE, GLOBAL PBC Study Group. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol. 2020 Jul; 115 (7):1066-1074
    View PubMed
  37. Trauner M, Gindin Y, Jiang Z, Chung C, Subramanian GM, Myers RP, Gulamhusein A, Kowdley KV, Levy C, Goodman Z, Manns MP, Muir AJ, Bowlus CL. Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. JHEP Rep. 2020 Feb; 2 (1):100060 Epub 2019 Dec 05
    View PubMed
  38. van Erp LW, Cunningham M, Narasimman M, Ale Ali H, Jhaveri K, Drenth JPH, Janssen HLA, Levy C, Hirschfield GM, Hansen BE, Gulamhusein AF. Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. Liver Int. 2020 Feb; 40 (2):382-392 Epub 2019 Dec 20
    View PubMed
  39. Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020 Feb; 17 (2):93-110 Epub 2019 Dec 09
    View PubMed
  40. Murillo Perez CF, Hirschfield GM, Corpechot C, Floreani A, Mayo MJ, van der Meer A, Ponsioen CY, Lammers WJ, Parés A, Invernizzi P, Carbone M, Maria Battezzati P, Nevens F, Kowdley KV, Thorburn D, Mason AL, Trivedi PJ, Lindor KD, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Janssen HLA, Hansen BE, Gulamhusein A, GLOBAL PBC Study Group. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019 Nov; 50(10):1127-1136. Epub 2019 Oct 17.
    View PubMed
  41. Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HLA, Hansen BE, Global PBC Study Group. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2019 Sep; 17(10):2076-2084.e2. Epub 2019 Jan 04.
    View PubMed
  42. Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep; 70 (3):788-801 Epub 2019 Mar 10
    View PubMed
  43. Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: Current and future therapeutic options. Liver Int. 2019 Jun; 39(6):1002-1013. Epub 2019 Mar 07.
    View PubMed
  44. Onofrio FQ, Hirschfield GM, Gulamhusein AF. A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist. Gastroenterol Hepatol (N Y). 2019 Mar; 15 (3):145-154
    View PubMed
  45. Moayedi Y, Fan CPS, Gulamhusein AF, Manlhiot C, Ross HJ, Teuteberg JJ, Khush KK. Current Use of Hearts From Hepatitis C Viremic Donors. Circ Heart Fail. 2018 Dec; 11 (12):e005276
    View PubMed
  46. Moayedi Y, Gulamhusein AF, Ross HJ, Teuteberg JJ, Khush KK. Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience. Clin Transplant. 2018 Jul; 32 (7):e13308 Epub 2018 June 21
    View PubMed
  47. Cheung AC, Gulamhusein AF, Juran BD, Schlicht EM, McCauley BM, de Andrade M, Atkinson EJ, Lazaridis KN. External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Hepatol Commun. 2018 Jun; 2(6):676-682. Epub 2018 Apr 24.
    View PubMed
  48. Gulamhusein AF, Hirschfield GM. Pathophysiology of primary biliary cholangitis. Best Pract Res Clin Gastroenterol. 2018 Jun-Aug; 34-35:17-25 Epub 2018 May 24
    View PubMed
  49. Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE, GLOBAL PBC Study Group. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Hepatology. 2018 May; 67(5):1920-1930. Epub 2018 Apr 06.
    View PubMed
  50. Reyes JL, Vannan DT, Vo T, Gulamhusein A, Beck PL, Reimer RA, Eksteen B. Neutralization of IL-15 abrogates experimental immune-mediated cholangitis in diet-induced obese mice. Sci Rep. 2018 Feb 15; 8(1):3127.
    View PubMed
  51. Gulamhusein AF, Kamath PS. The epidemiology and pathogenesis of gastrointestinal varices Techniques In Gastrointestinal Endoscopy. 2017 Apr; 19 (2):62-8
  52. Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, Eksteen B, Durie PR, Farkkila M, Müller T, Schramm C, Sterneck M, Weismüller TJ, Gotthardt DN, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma RK, Wijmenga C, Marschall HU, Milkiewicz P, Pares A, Kontula K, Chazouillères O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, Floreani A, Gulamhusein AF, Eaton JE, Schreiber S, Coltescu C, Bowlus CL, Luketic VA, Odin JA, Chopra KB, Kowdley KV, Chalasani N, Manns MP, Srivastava B, Mells G, Sandford RN, Alexander G, Gaffney DJ, Chapman RW, Hirschfield GM, de Andrade M, UK-PSC Consortium, International IBD Genetics Consortium, International PSC Study Group, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Anderson CA. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017 Feb; 49(2):269-273. Epub 2016 Dec 19.
    View PubMed
  53. Gulamhusein AF, Juran BD, Atkinson EJ, McCauley B, Schlicht E, Lazaridis KN. Low incidence of primary biliary cirrhosis (PBC) in the first-degree relatives of PBC probands after 8 years of follow-up. Liver Int. 2016 Sep; 36(9):1378-82. Epub 2016 Apr 28.
    View PubMed
  54. Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN. Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. Am J Gastroenterol. 2016 May; 111(5):705-11. Epub 2016 Mar 22.
    View PubMed
  55. Gulamhusein AF, Juran BD, Lazaridis KN. Genome-Wide Association Studies in Primary Biliary Cirrhosis. Semin Liver Dis. 2015 Nov; 35(4):392-401. Epub 2015 Dec 16.
    View PubMed
  56. Gulamhusein AF, Sanchez W. Liver transplantation in the management of perihilar cholangiocarcinoma. Hepat Oncol. 2015 Oct; 2(4):409-421. Epub 2015 Nov 06.
    View PubMed
  57. Nguyen GC, Wu H, Gulamhusein A, Rosenberg M, Thanabalan R, Yeo EL, Bernstein CN, Steinhart AH, Margolis M. The utility of screening for asymptomatic lower extremity deep venous thrombosis during inflammatory bowel disease flares: a pilot study. Inflamm Bowel Dis. 2013 Apr; 19 (5):1053-8
    View PubMed
  58. Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012 Sep; 107 (9):1298-304; quiz 1297, 1305 Epub 2012 July 03
    View PubMed
PST-20603691